Background {#Sec1}
==========

The development of immunotherapy targeting the PD1/PDL1 checkpoint inhibition pathway represents considerable progress in the treatment of many cancer types. Pembrolizumab is a humanized monoclonal antibody that blocks the interaction of PD-1 with its ligands, PD-L1 and PD-L2. It is FDA approved for the treatment of melanoma and NSCLC and was recently granted accelerated approval for the treatment of recurrent or metastatic head and neck squamous cell carcinoma in patients with disease progression on or after platinum-containing chemotherapy \[[@CR1]\]. Little is known regarding the effects of radiation following PD1 inhibition. We report a case of a patient who experienced excellent local control with immunotherapy followed by radiation therapy for relapsed oral cavity cancer.

Case presentation {#Sec2}
=================

A 66 year old woman with floor of mouth squamous cell carcinoma (SCC) presented to our institution after her second relapse. Originally diagnosed in 2006, she had undergone a composite resection with a flap reconstruction and bilateral neck dissections followed by post-surgical adjuvant radiotherapy for stage IVa (T4aN0M0) disease. Immunohistochemistry (IHC) staining for p16 was negative. In May of 2009, a resectable locoregional recurrence was detected and consequently treated with a composite resection utilizing a pectoralis flap reconstruction. In November of 2013, she presented with a second non-resectable locoregional relapse. She received carboplatin and paclitaxel for 4 cycles with a partial response (PR) after 2 cycles. The patient subsequently developed regional progression and was treated with weekly methotrexate and cetuximab and she achieved stable disease (SD) for 6 months. Later, she progressed locally and was enrolled into a trial utilizing single agent pembrolizumab. She had SD for 6 cycles (Fig. [1](#Fig1){ref-type="fig"}), and then suffered from local progression with a significant increase in the size of her neck mass, with painful ulceration and bleeding. Pembrolizumab was therefore discontinued. At this time restaging studies revealed no evidence of distant metastasis. She required multiple transfusions secondary to tumor hemorrhage and as a result was treated palliatively with radiation therapy to a total dose of 30 Gy directed at the mass. The patient experienced an excellent clinical response. Bleeding had resolved (Fig. [2](#Fig2){ref-type="fig"}) and her pain had greatly improved. A significant radiographic response was also noted on computed tomography (CT) scan, with tumor dimensions decreasing by 60 %, from 7.1 × 7.2 cm pre-radiation, to 5.9 × 3.4 cm, 6 weeks post-radiation.Fig. 1Change in largest dimensions of neck mass on CT scans over treatment period. **a** Prior to pembrolizumab. 8.8 × 5.9 cm. **b** Best response to pembrolizumab. 6 × 4 cm. **c** Progression on pembrolizumab. 7.1 × 7.2 cm. **d** Post radiation 5.9 × 3.4 cm Fig. 2Appearance of neck mass post pembrolizumab and radiation therapy. **a** Local control was achieved after 6 cycles of single agent pembrolizumab therapy. **b** The bleeding mass resolved after radiation therapy

Discussion {#Sec3}
==========

Pembrolizumab in head and neck cancer {#Sec4}
-------------------------------------

The strongest available data for checkpoint inhibitors in head and neck SCC are from an expansion cohort of a phase Ib study (KEYNOTE-012), utilizing pembrolizumab in the recurrent/metastatic setting (Table [1](#Tab1){ref-type="table"}). One hundred and ninety-two patients were enrolled. Confirmed objective response rate (ORR) was 17.7 % (95 % CI, 12.6--23.9 %; 7 complete responses \[CRs\], 27 PRs). Thirty three (17 %) patients achieved stable disease. ORR was seen in 21.9 % (95 % CI, 12.5--34.0 %) of HPV (human papilloma virus) positive and in 15.9 % (95 % CI, 10.0--23.4 %) of HPV negative patients. The median overall survival (OS) was 8.5 months (95 % CI, 6.5--10.5). These were patients who were heavily pretreated and a majority of them had more than two lines of previous therapy. Treatment-related adverse events (TRAEs) occurred in 122 (64 %) patients; 23 (12 %) patients had a grade 3--4 TRAE \[[@CR2]\].Table 1Ongoing trials on PD1 inhibitors in HNSCCAbbreviated Trial Name/NCT\#PhaseAgent(s)Study populationFindings/Expected Primary EndpointSafetyKEYNOTE-012/NCT01848834 Data updated from ASCO 2016IbPembrolizumabRecurrent/metastatic HNSCCORR 17.7 % (95 % CI, 12.6--23.9 %; 7 CRs, 27 PRs).\
HPV+ 21.9 %, HPV- 15.9 %.\
Median OS 8.5 mo (95 % CI, 6.5--10.5).Grade 3--4; 12 %\
No treatment related deathsKEYNOTE-055/NCT02255097 Presented ASCO 2016IIPembrolizumabRecurrent/metastatic HNSCC, progressed on platinum and cetuximabORR 18 % (95%CI 9--31); HPV+ 22 %, HPV- 16 %\
SD 18 %Grade 3--5; 20 %KEYNOTE-040/NCT02252042 OngoingIIIPembrolizumab VS Chemotherapy (methotrexate, docetaxel or cetuximab)Recurrent/metastatic HNSCCPFS\
OSKEYNOTE-048/NCT02358031 OngoingIIIPembrolizumab VS Pembro + cis/carbo + 5FU VS Cetuximab + cis/carbo + 5FUFirst line treatment for recurrent/metastatic HNSCCPFSCheckMate141/NCT02105636 Presented AACR 2016IIINivolumab VS Chemo (methotrexate, docetaxel or cetuximab)Recurrent/metastatic HNSCC1 year OS; nivo 36 %, chemo 16.6 %\
Median OS; nivo 7.5 mon, chemo 5.1 months

Radiation therapy and immunotherapy {#Sec5}
-----------------------------------

The effects of radiation following PD1 inhibition are unknown. Current data come from the concurrent administration of immune checkpoint inhibitors with radiotherapy. Radiation is thought to enhance antitumor immune responses by causing inflammatory cell death, major histocompatibility complex (MHC) I upregulation, and release of antigens that are taken up by dendritic cells \[[@CR3]\]. Mouse models have shown increased PD-L1 expression in tumors following irradiation \[[@CR4]\]. The abscopal effect; or the phenomenon in which tumor regression occurs at sites distant from the site of radiation, has been documented in melanoma and NSCLC patients who underwent radiation with ipilimumab, a CTLA-4 (cytotoxic T-lymphocyte-associated protein 4) checkpoint inhibitors \[[@CR5], [@CR6]\]. This further supports the concept of synergistic activity between checkpoint inhibitors and radiation.

Identifying the most beneficial timing for combined radiotherapy and immunotherapy remains a challenge. If radiation is given prior to, or concurrently with immunotherapy, immunotherapy may be more effective with tumor specific antigens originally generated by radiotherapy. On the other hand, if immunotherapy is delivered before radiotherapy, the active immune microenvironment may maximize radiation efficacy \[[@CR7]\]. In the present case, radiotherapy was given immediately following discontinuation of pembrolizumab in an attempt to control bleeding. The excellent response seen in the present case may be attributed from the synergistic effect of pembrolizumab.

One possible disadvantage of the concurrent administration of checkpoint inhibitors and radiation is the potential for added toxicities. In the present case, it is probable that the risk of adverse events (AE) was mitigated by the sequential delivery of therapy. In an analysis of 29 unresectable/metastatic melanoma patients who underwent radiation while receiving ipilimumab, the authors concluded that concurrent therapy was not associated with higher than expected rates of AEs, nor did it invalidate the palliative effects of radiation or survival benefits from ipilimumab \[[@CR8], [@CR9]\].

Several clinical trials are evaluating combined radiotherapy and checkpoint inhibitors in head and neck SCC (Table [2](#Tab2){ref-type="table"}). The phase Ib study of cetuximab, ipilimumab and intensity modulated radiation therapy (IMRT) in stage III-IVa HPV+ oropharyngeal SCC (NCT01935921) and the phase II study of concurrent versus sequential pembrolizumab, cisplatin and IMRT in stage III-IVb head and neck SCC are currently accruing patients (NCT0277385).Table 2Ongoing studies on PD1 inhibitors and radiation therapy in HNSCCAbbreviated Trial Name/NCT\#PhaseAgent(s)Study populationExpected Primary EndpointNCT01935921IbCetuximab, ipilimumab and IMRTstage III-IVa\
HPV+ OPSCCDose limiting toxicities (DLT)RTOG 3504\
NCT02764593III w/phase I lead inNivolumab and cisplatin CRTstage III-IV, intermediate to high risk HNSCCDLT for phase INCT02777385IIConcurrent vs sequential pembro, cisplatin and IMRTstage III-IVb\
HNSCC1 year PFS\
1 year failure rate\
Acute toxicity ratesHN003\
NCT02775812IAdjuvant pembro, cisplatin and IMRThigh risk stage III-IV HSNCCDLTNCT02641093IIAdjuvant pembro, cisplatin and IMRThigh risk stage III-IV HSNCCTreatment related adverse events (TRAE)\
Disease free survival (DFS)

Conclusion {#Sec6}
==========

As we await further data, a trial of radiation following immunotherapy could be considered for disease control in selected patients.
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